CTA - 医索

找到约 122 条结果

Safety, tolerability and efficacy of 21Pb-DOTAMTATE asa targeted alpha therapy for subjects with unresectableor metastatic somatostatin receptor-expressinggastroenteropancreatic neuroendocrine

医客学院 - 会议报告集

Randomized phase lllll trial of gemcitabine plusnab-paclitaxel versus. concurrentchemoradiotherapy with S-1 as neoadjuvanttreatment for borderline resectable pancreaticcancerGABARNANCE study

医客学院 - 会议报告集

Nivolumab plus ipilimumab vs lenvatinib or sorafenib asfirst-line treatment for unresectable hepatocellularcarcinoma first results from CheckMate 9DW

医客学院 - 会议报告集

NCIETCTN 10476 A Randomized, Phase 2 Study ofcombination Atezolizumab and Varlilumab(CDX-1127) withor without addition of Cobimetinib in Previously TreatedUnresectable Biliary Tract Cancer

医客学院 - 会议报告集

Development and validation of Al-assisted transcriptomicsignatures to personalize adjuvant chemotherapy in patientswith resectable pancreatic ductal adenocarcinoma

医客学院 - 会议报告集

Outcomes with Perioperative Durvalumab in Patientswith Resectable NSCLc and Baseline N2 Lymph NodeInvolvement(N2 R-NSCLC)

医客学院 - 会议报告集

Neoadjuvant nivolumab plus chemotherapy vschemotherapy in patients with resectable NSCLC4-year update from CheckMate 816

医客学院 - 会议报告集

Managing Expectations WithAntibody-Drug Conjugates in Non-Small Cell Lung Cancer

医客学院 - 会议报告集

Global Retrospective Study Comparing Consolidation ALK TKl to Durvalumab or Observation after Chemoradiation in Unresectable Locally Advanced ALK NSCLC

医客学院 - 会议报告集

Feasibility and safety of neoadjuvant nivolumab and chemotherapy for resectable diffuse pleural mesotheliomas (DPM) Results of a prospective pilot study

医客学院 - 会议报告集

首页
上一页
1
2
3
4
5
...
12
13
下一页
尾页

今日实时热搜